Mirum Pharmaceuticals
MIRM
159 hedge funds and large institutions have $1.55B invested in Mirum Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 68 increasing their positions, 31 reducing their positions, and 17 closing their positions.
119% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 31
88% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 17
62% more capital invested
Capital invested by funds: $956M → $1.55B (+$590M)
30.63% more ownership
Funds ownership: 97.14% → 127.77% (+31%)
9% more funds holding
Funds holding: 146 → 159 (+13)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
13% less call options, than puts
Call options by funds: $2M | Put options by funds: $2.29M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$120M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$57.8M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$45.4M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$31.3M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$18.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RVM
RiverVest Venture Management
St. Louis,
Missouri
|
-$41.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.5M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$8.8M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$5.96M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$5.04M |
MIRM Hedge Fund Activity: Q3 2023 in Review
159 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q3 2023, worth a combined $1.55B — up 62% from $956M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new MIRM positions and 17 closed out — a net gain of 15 holders — while 68 added to existing stakes and 31 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $120M. The largest seller was RiverVest Venture Management, exiting entirely with an estimated $41.9M sold.
- 159 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q3 2023, up from 146 in Q2 2023.
- Funds reported $1.55B of Mirum Pharmaceuticals stock for Q3 2023, up 62% quarter-over-quarter.
- 32 funds opened new Mirum Pharmaceuticals positions in Q3 2023 and 17 closed out, a net change of +15 holders.
- The largest Mirum Pharmaceuticals buyer in Q3 2023 was BVF Inc, an estimated $120M added.
- The largest Mirum Pharmaceuticals seller in Q3 2023 was RiverVest Venture Management, an estimated $41.9M sold.
Based on aggregated 13F filings for Q3 2023.